# BBB Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bbb-technology

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.bbbtech.com
- Total disclosed funding: $22M
- Latest round: Series B (Oct 31, 2018)
- Investors on record: 7

## About

BBB Technology is a South Korean company focused on developing advanced diagnostic solutions using its proprietary technology to deliver rapid and accurate test results for various health conditions.Founded in 2014 in Seoul, South Korea, BBB Technology specializes in diagnostic solutions. The company has engaged in 4 funding rounds, with the most recent being a Series B round on October 31, 2018, where they raised KRW 16.5 billion from investors including Bokwang Venture Capital and SK Securities. The CEO, who is also the founder, has a history of involvement in similar ventures.BBB Technology, through its subsidiary MARK-B, specializes in advanced diagnostic solutions utilizing its patented Magnetic Electrochemical Sandwich ImmunoAssay (MESIA) technology. This offering provides rapid and highly accurate quantitative results for various biomarkers related to conditions such as tumors, cardiovascular diseases, and infectious diseases. The fully automated system minimizes preprocessing and delivers results in minutes, serving healthcare providers, diagnostic labs, and hospitals mainly across North America, Europe, and Asia.MARK-B operates under a B2B model, engaging with hospitals and laboratories for its diagnostic solutions. Revenue is generated through direct sales of diagnostic equipment, consumable test kits, and software services. The MARK-B™ analyzer is offered alongside service agreements for ongoing consumable supplies and software updates, ensuring clients have continuous access to diagnostic capabilities, supported by a cloud server for data management.In October 2018, BBB Technology raised KRW 16.5 billion in Series B funding to accelerate the mass production and commercialization of its Point of Care testing platform. The company aims to expand its reach into new markets and geographic regions, although specific targets and timelines have not been disclosed. The funds will also support the launch of new products currently being designed to enhance their offerings in the diagnostics space.

## Funding rounds

- Series B, Oct 31, 2018, $14M — KDB Bank, Bokwang Venture Capital, SK Securities, Dong Wha PHARM CO., LTD., Mirae Asset Capital
- Series A, Aug 1, 2016, $4.9M — Mirae Asset Capital, Posco Investment, ID Ventures
- Series A, Jul 1, 2016, $2.3M — Posco Investment, ID Ventures

## Investors

- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series A
- ID Ventures (https://capitalatlas.ai/funds/id-ventures) — Series A
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series A, Series B
- KDB Bank — Series B
- Bokwang Venture Capital (https://capitalatlas.ai/funds/bokwang-venture-capital) — Series B
- SK Securities — Series B
- Dong Wha PHARM CO., LTD. — Series B